A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED PHASE 3 EFFICACY AND SAFETY STUDY OF BENRALIZUMAB IN PATIENTS WITH SEVERE NASAL POLYPOSIS (OSTRO)
- Registry ID
- D3252C00001
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ASTRAZENECA CANADA INC
- Start date
- 2018-02-01
- Completion date
- 2020-07-31
- Last update
- 2017-12-27
Conditions
Related clinical trials
- A DOUBLE-BLINDED EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ITEPEKIMAB IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP) WHO PARTICIPATED IN EITHER EFC18418 OR EFC18419 CLINICAL STUDIES
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, 52-WEEK PHASE 3
TRIAL TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ITEPEKIMAB IN ADULT
PARTICIPANTS WITH INADEQUATELY-CONTROLLED CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, 52-WEEK PHASE 3
TRIAL TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ITEPEKIMAB IN ADULT
PARTICIPANTS WITH INADEQUATELY-CONTROLLED CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
- A MULTICENTRE, SINGLE-ARM, PHASE 3B STUDY TO ASSESS CHANGES IN SYMPTOMS IN ADULT PARTICIPANTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS INITIATING TREATMENT WITH TEZEPELUMAB (ESSENCE)
- A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL
GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/LY3650150 IN
ADULT PARTICIPANTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS ON BACKGROUND
INTRANASAL CORTICOSTEROIDS
- A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED PHASE 3 EFFICACY AND SAFETY STUDY OF TEZEPELUMAB IN PARTICIPANTS WITH SEVERE CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (WAYPOINT)
View on source registry